Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF
Conditions
Brief summary
The pathogenesis of idiopathic pulmonary fibrosis (IPF) is incompletely understood but recurrent epithelial injury occurs which evokes the coagulation cascade. Thrombin is produced as a result and is over expressed in IPF patients, so may be important in propagating disease activity. We aim to recruit patients with IPF and then complete FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET (positron emission tomography) scans pre and post manipulation of the coagulation cascade to assess the role of this biological pathway in disease activity. Previous studies from our institution have demonstrated increased FDG avidity in the lungs of patients with IPF (assessed using FDG PET scans) but to date the cells and pathways responsible for this signal have not been identified and thus need further exploration.
Detailed description
Patients with IPF who meet all the inclusion criteria (and none of the exclusion criteria) will be assessed and invite to participate. They will undergo baseline assessment with lung function, 6 minute walk test and health quality assessments. Blood tests will assess the pro-coagulant state of these individuals. They will undergo a baseline FDG PET scan followed by manipulation of the coagulation cascade with 24 days (+/- 3 days) dabigatran. They will then complete a second FDG PET, health quality assessments and blood tests to demonstrate target engagement.
Interventions
DRUGDabigatran
Anti-coagulant
RADIATIONFDG PET scan
Scan using PET combined with a high resolution CT scan (HRCT)
Sponsors
University College, London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* A diagnosis of IPF based on multi disciplinary meeting discussion following review of the clinical history, characteristic features on HRCT (high resolution CT scan) and/or usual interstitial pneumonia (UIP) histology. * Written informed consent obtained from subject.
Exclusion criteria
* Age \<40 or \>80 years * Renal impairment as defined by a creatinine clearance of \<30 millilitres/min * Significant liver impairment with evidence of synthetic dysfunction * Any contraindication to anti-coagulation including previous life threatening or serious bleed or bleeding tendency. * Co-administration of any concomitant medications prohibited in full protocol. N-acetyl cysteine, prednisolone up to 10mg daily and pirfenidone are permitted. * Pregnant, breast feeding or unwilling to practice birth control during participation in the study (females of child bearing age). * Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient of the quality of the data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demonstrate a change in FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) avidity | Approximately 4 weeks | FDG avidity describes the degree of tissue uptake of the labelled glucose. It is a numerical continuous variable. It is calculated from the scan using several methods, manually on a workstation and using a mathematical modelling computer programme. The main number generated is called the standardised uptake value (SUV) and the higher the number the higher the metabolic activity in the area. The degree of activity will be quantified for each individual and compared with standard measures of disease activity i.e. lung function measures and quality of life questionnaires. For each individual the change in the SUV measure will be analysed from the scan performed before and then after manipulation of the coagulation cascade. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Demonstrate changes in various coagulation factors | Approximately 4 weeks | This patient group have demonstrated a hyper coagulable state in a number of previous studies. We will demonstrate this using blood tests prior to administration of dabigatran. The coagulation markers (a blood test, many used in standard clinical practice) will be repeated during treatment to demonstrate target engagement. |
Contacts
Primary ContactJoanna C Porter, PhD FRCP
Backup ContactHelen S Garthwaite, MB BS MRCP
Outcome results
None listed